New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population

Core Insights - iRhythm Technologies presented new data at the 18th Asia Pacific Heart Rhythm Society and Japanese Heart Rhythm Society Joint Scientific Session, highlighting the performance of its Zio long-term continuous ECG monitoring system in diverse patient populations [1][7]. Group 1: Study Overview - The study, led by Dr. Hiro Kawata, analyzed 408,470 U.S. patients monitored between 2018 and 2022, comparing device compliance, performance, and arrhythmia detection between Asian and non-Asian populations [2][5]. - The analysis aimed to determine if racial and cultural differences impact the effectiveness of ambulatory cardiac monitoring [3]. Group 2: Key Findings - The findings indicated no significant differences in wear time, analyzable time, or arrhythmia detection yield between Asian and non-Asian patients, supporting the reliability of the Zio system across diverse populations [5][6]. - Median wear time was 13.6 days for Asian patients compared to 13.0 days for non-Asian patients, while analyzable ECG duration was 12.9 days for Asians versus 12.2 days for non-Asians [8]. - The arrhythmia detection rates were comparable, with Asian patients showing a 14.0% detection rate for atrial fibrillation compared to 14.3% for non-Asians [8]. Group 3: Implications for Japan - As Japan's population ages, the demand for advanced cardiac monitoring is increasing, with approximately 1.6 million tests prescribed annually [9]. - iRhythm's Zio ECG system, which allows for up to 14 days of continuous monitoring, represents a significant advancement over traditional monitoring options in Japan [10]. - The company is collaborating with local investigators to expand evidence and support the adoption of the Zio system in Japanese clinical practice [11]. Group 4: Supporting Evidence - The analysis adds to the growing body of evidence supporting the Zio LTCM service, which has been validated in previous studies such as CAMELOT and AVALON [12]. - iRhythm has generated over 2 billion hours of curated heartbeat data and more than 12 million patient reports, reinforcing its commitment to improving cardiac arrhythmia detection and management [13].